You are here: Home Published Research Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

Bjarne Robberstad, Carl R Frostad, Per E Akselsen, Kari J Kværner, and Aud KH Berstad (2011)

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

Vaccine, 29(47):8564–8574.

A seven valent pneumococcal conjugate vaccine (PCV7) was introduced in the Norwegian childhood immunization programme in 2006, and since then the incidence of invasive pneumococcal disease has declined substantially. Recently, two new second generation pneumococcal conjugate vaccines have become available, and an update of the economic evidence is needed. The aim of this study was to estimate incremental costs, health effects and cost-effectiveness of the pneumococcal conjugate vaccines PCV7, PCV13 and PHiD-CV in Norway.

Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cost-Benefit Analysis, Female, Heptavalent Pneumococcal Conjugate Vaccine, Humans, Infant, Infant, Newborn, Male, Meningitis, Pneumococcal, Middle Aged, Models, Statistical, Norway, Otitis Media, Pneumococcal Vaccines, Pneumonia, Pneumococcal, Quality-Adjusted Life Years, Vaccines, Conjugate, Young Adult
Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cost-Benefit Analysis, Female, Heptavalent Pneumococcal Conjugate Vaccine, Humans, Infant, Infant, Newborn, Male, Meningitis, Pneumococcal, Middle Aged, Models, Statistical, Norway, Otitis Media, Pneumococcal Vaccines, Pneumonia, Pneumococcal, Quality-Adjusted Life Years, Vaccines, Conjugate, Young Adult
 
Document Actions